Public Employees Retirement System of Ohio Invests $538,000 in Keros Therapeutics, Inc. $KROS

Public Employees Retirement System of Ohio purchased a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 50,324 shares of the company’s stock, valued at approximately $538,000. Public Employees Retirement System of Ohio owned approximately 0.25% of Keros Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently modified their holdings of the company. AQR Capital Management LLC purchased a new position in Keros Therapeutics during the 1st quarter worth $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Keros Therapeutics by 15.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock worth $227,000 after buying an additional 2,982 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after buying an additional 205,022 shares during the period. Creative Planning grew its position in shares of Keros Therapeutics by 40.2% during the 2nd quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after buying an additional 6,948 shares in the last quarter. Finally, Rhumbline Advisers grew its position in shares of Keros Therapeutics by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock worth $692,000 after buying an additional 7,146 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on KROS. Zacks Research raised shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 27th. Wells Fargo & Company cut their target price on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 4th. Leerink Partners lowered their price target on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Keros Therapeutics has an average rating of “Hold” and an average target price of $20.50.

Insider Buying and Selling at Keros Therapeutics

In other news, insider Lorena Raquel Lerner sold 3,568 shares of Keros Therapeutics stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the transaction, the insider owned 27,559 shares of the company’s stock, valued at $283,582.11. The trade was a 11.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 5,343 shares of company stock valued at $54,985. 12.60% of the stock is currently owned by company insiders.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $11.17 on Friday. Keros Therapeutics, Inc. has a 1-year low of $9.69 and a 1-year high of $22.55. The business has a fifty day moving average price of $10.83 and a 200 day moving average price of $11.22. The stock has a market capitalization of $221.50 million, a P/E ratio of -3.02 and a beta of 1.01.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. As a group, equities research analysts anticipate that Keros Therapeutics, Inc. will post -5.27 earnings per share for the current fiscal year.

Keros Therapeutics announced that its board has approved a share buyback plan on Wednesday, September 9th that permits the company to buyback $5.00 million in shares. This buyback authorization permits the company to reacquire up to 2.3% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.